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EDITORIAL
Vitamin D, the kidney and calcium homeostasis
In 1919 Sir Edward Mellanby produced experimental
rickets for the first time and reported on its subsequent cure
and prevention with cod liver oil. Within the next six years,
Steenbock and associates discovered that antirichitic
activity could be produced in animals and food by ultra-
violet irradiation. During the 1920's and 1930's accelerated
interest in this "antirichitic activity" led to the synthesis
of the natural provitamin, 7-dehydrocholesterol, and ulti-
mately to the isolation and identification of vitamin D [1].
In the last 20 years, vitamin D has been shown to play a
pivotal role in the biochemical control of intestinal calcium
absorption and bone remodeling. Of utmost significance
was the discovery that vitamin D in itself was inert and
that metabolic activation was essential to its biological ex-
pression. Today, in fact, the term "vitamin" D is a mis-
nomer for all practical purposes since its endogenous pro-
duction by the skin, distribution by the blood stream, the
negative feedback control of its metabolism, and its mode
of action through the stimulation of protein synthesis, all
resemble hormonal rather than dietary vitamin activity.
Intermediary metabolism of vitamin D. Within the last
decade, considerable knowledge has accumulated regarding
the metabolism of vitamin D and its biological activity in
health and disease. In man, ultraviolet irradiation iso-
merizes 7-dehydrocholesterol in skin to vitamin D3 resulting
in an average vitamin D3 content of approximately 3.2 g/g
tissue or 17 lU/cm2 of skin [2]. The preformed vitamin D3
is then absorbed into the micro-circulation and transported
in plasma while bound to a specific globulin of d> 1.21
and a molecular weight of approximately 60,000 [3, 4].
Dietary vitamin D2 (ergocalciferol) or vitamin D3 (chole-
calciferol) are absorbed bound to lipoproteins primarily
from the duodenum and jejunum into lymphatic channels
with both bile salts as well as intestinal lipids permissive
in this regard [5]. The absorbed vitamin D2 or D3 then
admixes with endogenously synthesized vitamin D3 and is
either sequestered in storage depots or metabolically trans-
formed. Adipose tissue and muscle appear to be major
storage sites for vitamin D3 [6, 7], presumably serving as a
source of the vitamin during dietary deprivation and/or
lack of sunlight exposure. Circulating vitamin D3 levels, as
determined by gas-liquid chromatographic techniques [8]
in subjects on routine diets, normally range between 8 and
45 ng/ml; at this plasma level, vitamin D3 disappears with
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a biological half-time of 19 to 25 hr [3, 9]. Endogenously
synthesized vitamin D3 (and presumably vitamin D2 as
well) are metabolized to their respective 25-hydroxylated
derivatives (i.e., 25-hydroxycholecalciferol and 25-hydroxy-
ergocalciferol) by a hepatic mitochondrial enzyme system
which requires reduced pyridine nucleotide and molecular
oxygen [10]. Although it has been established that the
25-hydroxylation conversion system in the liver is feedback-
regulated by the product of its action, the exact nature of
this servo-control mechanism is still poorly understood, as
is the role it plays in preventing the toxic effects of vita-
min D overdosage. The hydroxylated vitamin D metabolites
25-hydroxycholecalciferol (25HCC) and 25-hydroxyergo-
calciferol (25HEC), subsequently circulate bound to a alpha
globular protein indistinguishable from that which binds
the parent vitamin D, with a biological half-time of 13 to
19 days [3]. A recently developed competitive protein-
binding radio-ligand assay allows precise determination
of the 25-hydroxylated vitamin D derivatives [11, 12].
Unfortunately the method does not yet distinguish 25HCC
from 25HEC. Combined 25HCC-25HEC levels in normal
subjects, as quantitated by this technique, average 20.5
3.0 ng/ml [11]; a direct correlation exists between indi-
vidual 25HCC-25HEC values, vitamin D intake, exposure
to sunlight and total serum calcium values. 25-hydroxy-
lated forms of vitamin D represent the major circulating
vitamin D metabolites and a direct action of 25HCC
has been demonstrated on bone [13] and intestine [14]. It
has also been shown that 25HCC increases the proximal
tubular reabsorption of phosphate, and that this activity
is antagonistic to the phosphaturic effect of parathyroid
hormone [15].
Whereas the metabolic fates of 25HCC in intestine and
bone are still poorly defined, it is further hydroxylated to
either I ,25-dihydroxycholecalciferol (1 ,25DHCC) or
24,25-dihydroxycholecalciferol' (24,25DHCC) by a carbon
monoxide-sensitive mitochondrial system which also re-
quires reduced pyridine nucleotide and molecular oxygen
for maximal activity [16, 17]. Preliminary observations are
consistent with the view that the conversion of 25HCC to
either 1 ,25DHCC or 24,25DHCC is regulated by a second
servo-control mechanism modulated by circulating calcium,
1 Recent observations suggest that the second hydroxyl group
is in position "24" in this metabolite rather than position "21"
as previously reported.
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parathyroid hormone and calcitonin [18—21]. Parathyroid
hormone stimulates 1-hydroxylation of 25HCC to
1,25DHCC whereas calcitonin promotes 24-hydroxylation
of 25HCC to 24,25DHCC. In defense of this hypothesis
are the observations that thyroparathyroidectomized ani-
mals do not synthesize 1 ,25DHCC and that exogenous
administration of parathyroid hormone restores the renal
synthesis of 1,25DHCC to normal [20]. In addition,
whereas circulating 24,25 DHCC is undetectable in the
presence of parathyroid tissue, it has been isolated from
the plasma of a hypoparathyroid patient with known
"resistance" to vitamin D therapy [22]. The current pre-
vailing hypothesis is one which considers hypocalcemia as
a stimulus for parathyroid hormone secretion, the latter
stimulating the renal synthesis of 1,25DHCC which in turn
completes the negative feedback loop system of hormonal
control by stimulating the intestinal absorption and bone
mobilization of calcium (Fig. 1). In contrast, hyper-
calcemia, while decreasing the rate of parathyroid hormone
release, also stimulates calcitonin release, the combination
resulting in decreased 1,25 DHCC production, a stimulated
production of 24,25 DHCC and a decrease in both calcium
absorption and bone mobilization [21, 23]. Although the
metabolic fate of both 1,25 DHCC and 24,25 DHCC is still
unknown, accumulated evidence is consistent with the view
that 1,25 DHCC is "the" vitamin D3 metabolite which
governs intestinal calcium transport and bone resorption.
1,25 DHCC is four to thirteen times as effective as vita-
min D3 and over two times as effective as 25 HCC in
stimulating intestinal calcium transport [25].
The manner in which vitamin D metabolites exert con-
trol over calcium uptake and its transcellular migration is
purely conjectural. Preliminary observations suggest that
the diol or triol metabolites are initially bound to specific
cytosol proteins [26] prior to their incorporation onto
nuclear receptor sites where they ultimately affect either
the transcriptional process directly [27, 28] or regulate the
release or transport of nuclear-derived RNA. The final event
in the sequence is the generation of proteins essential for
calcium transport such as calcium-binding protein(s),
alkaline phosphatase(s) and ATPase(s) [29]. It has been
noted by some investigators that 1,25 DHCC but not
25 HCC induces calcium transport in rats previously treated
with actinomycin D [30, 31]. These findings suggest that
l,2SDHCC acts in the intestine by a process which does
not involve the retrieval of genetic information and that the
actinomycin D-sensitive component in the stimulated in-
testinal response to vitamin D is the conversion of 25 HCC
to 1,25 DHCC in the kidney.2 The fact that actinomycin D
fails to inhibit the intestinal effect of 1,25 DHCC does not
2 Studies with isolated tubules arc not in accord with this
theory since parathyroid hormone and extracellular calcium
ion have no regulatory effect on the renal tubular consumption
of 25 HCC or production of 1,25 DHCC [61].
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Fig. 1. Proposed interrelationship
between vitamin D and its metab-
olites, parathyroid hormone, cal-
citonin and calcium homeoslasis.
The dotted lines in the scheme
represent inhibition of either cal-
citonin or parathyroid hormone
release by hypocalcemia and hyper-
calcemia, respectively and the sub-
strate inhibition of enzymatic 25-
hydroxylation of vitamin D3 in the
liver.
24,25 DHCC
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migitate against the theory that the action of vitamin D on
the intestinal is mediated ultimately by transport proteins
or enzymes. The vitamin may still function in this regard
by activating certain protein precursors within the intestinal
cell.3 Unlike 25 HCC, 1,25 DHCC has a minimal effect on
the renal tubular reabsorption of phosphate. However,
1,25 DHCC does possess bone resorptive properties with
an in vitro effectiveness some 100 times that of the parent
25 HCC [32]. The preferential accumulation of 1,25 DHCC
in the nucleus of bone cells and the subcellular skeletal
distribution pattern of other vitamin D3 metabolites [33]
suggest a mechanism of action for 1,25 DHCC in bone that
resembles its influence on calcium translocation in the in-
testinal cell [27, 28]. Finally, although another triol meta-
bolite of vitamin D (25,26-dihydroxycholecalciferol) with
weak biological activity limited to the intestine has been
isolated from plasma [34], its origin and metabolic fate
has yet to be determined. On the basis of observations in
man and a variety of animal species, the current working
hypothesis depicts vitamin 133 primarily as an inert storage
substance, 25 HCC as the major circulating metabolite and
1,25 DHCC as the ultimate biologically active metabolite;
in concert with parathyroid hormone and calcitonin, they
control the intestinal absorption of calcium and the re-
modeling of bone.
Vitamin D and chronic renalfailure. Chronic renal failure
is attended by an acquired impairment of intestinal calcium
absorption, secondary hyperparathyroidism, and defective
maturation of both osteoid and mineral moieties of skeletal
tissue [35—40]. Although some of these derangements in
mineral metabolism are occasionally reversed temporarily
by chronic hemodialysis they are usually refractory to
dialytic therapy and may actually progress in an accelerated
fashion during treatment. Disordered mineral metabolism
in renal failure results in osteopenia, fracture, ectopic cal-
cification and sustained hyperparathyroidism, all of which
present a frustrating therapeutic challenge. So-called
"renal osteodystrophy" subsequently becomes resistant to
vitamin D therapy in that the requirement of the vitamin
to produce an effective sustained biological response is
increased when compared to dosages used in other non-
uremic malabsorptive or demineralizing pathological states.
Although the temporal relationship between the acquired
resistance to vitamin D and advancing uremia is still ill-
defined, it becomes evident when filtration rate is reduced
to 15 to 20 ml/min.
It has been demonstrated with biological assay techniques
that vitamin D activity (i.e., antirichitic activity) in the
serum of untreated patients with chronic uremia is lower
than that observed in either a well-fed healthy population
[41, 42] or in malnourished individuals with terminal
Date in defense of this hypothesis are considerable but presently
inconsistent with observations that complete inhibition of
RNA synthesis by actinomycin D or protein synthesis by
puromycin does not diminish 25 HCC consumption or
1,25 DHCC production by intact renal tubule [62].
cachexia [42]. In addition, the patient with terminal uremia
requires a greater intake of vitamin D and higher levels of
assayable anti-richitic activity for biological effectiveness
than does the normal individual [41]. This well-recognized
phenomenon of vitamin D resistance in renal failure has
been variably attributed to uremic toxins interfering with
the normal conversion of vitamin D or its more active
metabolites or the response of the end organs to these
metabolites. Recent studies with radioisotopic forms of
vitamin D3 and 2SHCC in subjects with renal failure [43,
44], in anephric animals [17, 45], and in animals with ex-
perimentally induced chronic renal failure [46], have fo-
cused attention on the loss of kidney cells rather than on
the loss of renal excretory function as being responsible
for the defect in intestinal calcium transport activity. All
things being equal, one would anticipate that a reduction
in kidney mass would result in decreased renal production
of 1,25 DHCC. It also seems logical to assume that the
subsequent reduction in the intestinal mucosal concen-
tration of 1,25 DHCC leads to progressive decrements
in calcium absorption. Results demonstrating that small
doses of 1,25 DHCC augment calcium absorption and
raise the serum calcium of uremic man are consistent with
this hypothesis [47], as is the frequent failure of hemo-
dialysis to reverse the progression of calcium malabsorp-
tion, renal osteodystrophy and vitamin D resistance.
Alterations in the metabolic fate of 25 HCC, albeit well
documented in uremic man and animals with experimen-
tal renal failure, do not as yet completely explain the cal-
cium malabsorption of uremia nor a variety of other in-
dependent observations. Defects in calcium absorption are
noted in experimental renal insufficiency at a time when
the metabolism of vitamin D and the tissue localization of
its metabolites are normal [48]. The possibility obtains
that one or more uremic toxins may impose certain con-
ditional alterations in the orderly sequence of intestinal
cell multiplication, morphologic maturation, and in the
translational and transcriptional processes normally regu-
lating intestinal protein synthesis [49]. These vitamin D-
independent changes might result in structural or catalytic
defects in cellular protein components of the calcium trans-
port system such as the calcium-binding protein(s) and
ATPase(s), and consequently limit the translocation of
dietary calcium across the intestinal cell. Since the uptake
and release of calcium by intestinal mitochondria is funda-
mental to its cellular transport [29], the documented distor-
tion of intestinal mitochondrial metabolism in uremia [50]
may add to the sluggish migration of calcium through the
mucosal cell. Since plasma levels of 2SHCC-2SHEC do
increase in uremic subjects during vitamin D therapy it
has been assumed that hepatic 25-hydroxylation proceeds
normally. However, patients on chronic hemodialysis can
be separated into those with normal circulating 25 HCC-
2SHEC levels and osteitis fibrosa cystica and others with
low 2SHCC-2SHEC levels and osteomalacia [51] and rats
with experimental renal insufficiency of five to nine weeks
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duration have lower circulating 25 HCC levels than their
pair-fed controls [39]. In addition, it has been demonstrated
that vitamin D therapy alone reverses the osteomalacia
of bilaterally nephrectomized patients on hemodialysis [52]
and that 25HCC, in doses of 6,000 to 12,000 lU/day is
effective therapy for uremic bone disease in individuals
refractory to vitamin D in equivalent dosage [53]. These
findings suggest that in end-stage renal failure, refrac-
toriness to vitamin D may involve end-organ failure (i.e.,
mitochondrial metabolism or protein synthesis) second-
ary to a variety of uremic toxin(s). Alterations in the
metabolism of vitamin D or its hydroxylated metabolites
may also result in the accumulation of structurally related
abnormal metabolites which compete with 1,25 DHCC for
receptor sites in the nuclei of specific target organs. Alter-
natively, the possibility exists that tissue l,25DHCC re-
ceptor sites exhibit a relative rather than an absolute
specificity for diol and triol vitamin D-related sterols and
as such are readily available to vitamin D3, and 25 HCC as
well. Demonstrated in vitro effectiveness of vitamin D3,
dihydrotachysterol and 25 HCC on intestinal calcium ab-
sorption is compatible with this hypothesis [54]. It may
also be premature to assume that negative feedback regu-
latory mechanisms for 25 HCC and 1,25 DHCC generation
by the liver and kidney respectively (Fig. 1) are intact
in the uremic subject. Although in theory, the attendent
hypocalcemia and resultant secondary hyperparathyroid-
ism should compensate for the decrease in 1,25 DHCC
production anticipated by the loss of renal mass, this does
not appear to be the case since 1,25DHCC production is
decreased in animals and humans with terminal renal
failure and secondary hyperparathyroidism. This relative
inefficiency of the renal servo-control mechanism for
1,25 DHCC production may represent another example of
end-organ resistance to parathyroid hormone often com-
plicating the uremic syndrome [37].
Accumulated knowledge in the intermediary metabolism
of vitamin D3 and the defects in this pathway in chronic
renal failure should lend itself to a more rational ap-
proach to the uremic patient. For example, the pro-
cedure of bilaterally nephrectomizing patients under-
going dialysis and programmed for renal transplanta-
tion should be tempered by the consideration that nephrec-
tomy will remove those residual renal cells which are
capable of synthesizing 1,25DHCC and may ultimately
lead to a progressive renal osteodystrophy which may be
quite refractory to vitamin D therapy. Although 25HCC
[53, 55] or l,25HCC [49] may prove to be effective thera-
peutic agents, the supply of the former is quite limited and
the synthesis of l,25DHCC too expensive to make its
routine availability practical. In addition, both 25 HCC and
l,25DHCC may be inappropriate therapeutic agents in
chronic renal failure since their ability to activate intestinal
calcium absorptive mechanisms is most probably accom-
panied by an exaggeration of the already increased bone
resorption. Thus the reported hypercalcemic-hyperphos-
phatemic response of uremic patients to limited 1,25 DHCC
therapy [47] may reflect a combination of stimulated in-
testinal calcium transport and skeletal osteolysis. Until the
exact nature of the acquired defect in vitamin D metab-
olism uremia is defined, and until the entire spectra of
the in vivo biological effectiveness of various metabolites
is established, prolonged therapy with either 25 HCC or
1,25 DHCC should be conditioned with moderation and
careful surveiliance.
It has been reported that dihydrotachysterol (DHT) in
doses of 0.25 mg/day is effective in promoting healing of
the bone disease in dialyzed patients [56]. Dihydrotachy-
sterol like cholecalciferol requires hepatic enzymatic
hydroxylation in position 25, before it becomes biologically
effective [57]. Chemically synthesized 25-hydroxydihydro-
tachysterol3 is more potent and faster acting than dihydro-
tachysterol3 in the mobilization of bone mineral and is also
more antirichitic than dihydrotachysterol3 and more effec-
tive in promoting elevations of plasma calcium in hypo-
parathyroidism [58, 59]. The biological effectiveness of
25-hydroxydihydrotachysterol3 may depend on its struc-
tural characteristics since the trans-diene configuration of
the dihydrotachysterol molecule (Fig. 2) confers a posi-
tional change in its 3-hydroxyl group so that it occupies a
position sterically analogous to the 1-hydroxyl group in
the cis-diene configuration of 1,25 DHCC (Fig. 2). Thus in
the absence of further l-hydroxylation by the kidney,
25-hydroxydihydrotachysterol3 might possess an affinity
for intestinal or bone receptor sites equal to that of
1,25DHCC. This is undoubtedly an oversimplication be-
cause the A-ring geometry of the dihydrotachysterol differs
25 HCC 1,25 DHCC
OH OH
25 HDHT3 5,6-trans-25 HCC
Fig. 2. Structural similarities between 25-hydroxycholecalciferol
(25HCC), 1,25-dihydroxycholecalciferol (1,25DHCC), 25-hydr-
oxydihydrotachysterol3 (25H DHT3) and 5,6-trans 25-hydroxy-
cho1eca1cferol (5,6-trans 25HCC).
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substantially from vitamin D. However, such a closely
related compound might be able to overcome strict stereo-
chemical constraints by mass action. This theory is also
compatible with the observed structural specificities for
both the intestinal and bone receptor sites for a variety of
biologically active "vitamin D3-like" compounds. Those
with side chains of vitamin D3 or dihydrotachysterol3 act
perferentially on the intestine whereas compounds with the
side chain of vitamin D2 (ergocalciferol) or dihydrotachy-
sterol2 act perferentially to mobilize skeletal mineral [59].
The ideal drug of choice in the management of the
bone disease of renal failure is one which not only
stimulates the intestinal absorption of calcium with the
effectiveness of 1,25DHCC but one which is also devoid
of the bone mobilizing effect of this triol metabolite of
vitamin D3. Recent attempts to develop a compound with
these unique properties have led to the synthesis of the
5,6-trans isomer of 2511CC. Compared to 25HCC, the
5,6-trans isomer has its A-ring rotated 1800, with the
33-hydroxyl group in the same geometrical position as the
1-hydroxyl of 1,25DHCC (Fig. 2). Since 5,6-trans 25HCC
reportedly is more active than 25HCC in stimulating in-
testinal transport in the anephric state and demonstrates
little if any potential to induce bone resorption in vitro [601,
it becomes one of the most promising drugs for the simul-
taneous reversal of the calcium malabsorption and the
osteodystrophy associated with uremia. The knowledge
derived from continued investigation with 5,6-trans 25 HCC
and structurally related synthetic analogues in acute
anephric or chronic uremic states should add consider-
ably to existing concepts on the specific function of indi-
vidual biologically active vitamin D metabolites and their
modes of action on kidney, intestine and bone.
Louis V. Avioli
St. Louis, Missouri
Reprint requests to Dr. L. V. Avioli, Washington Univer-
sity School of Medicine, The Jewish Hospital of St. Louis, 216
S. Kingshighway, St. Louis, Missouri 63110, U.S.A.
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